GlobeNewswire

Navigators Announces Second Quarter 2019 Dividend

Share

STAMFORD, Conn., May 09, 2019 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) announced today that its Board of Directors declared a cash dividend of $0.07 per share of common stock for the second quarter of 2019. The dividend will be payable on June 4, 2019 to the Company's stockholders of record at the close of business on May 20, 2019.

About Navigators
The Navigators Group, Inc. (Nasdaq: NAVG) is a global specialty insurance holding company. We provide customized insurance solutions designed to protect clients from the complex risks they face. For 45 years, Navigators has added value for broker partners and their clients—both in underwriting and in claims—through the depth and quality of our technical and industry expertise. Industries we serve include maritime, construction, energy, environmental, professional services and life sciences. Headquartered in Stamford, Connecticut, Navigators has offices in the United States, the United Kingdom, Continental Europe and Asia.

This press release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  Whenever used in this release, the words "estimate," "expect," "believe" or similar expressions are intended to identify such forward-looking statements.  Forward-looking statements are derived from information that we currently have and assumptions that we make. We cannot assure that results that we anticipate will be achieved, since results may differ materially because of known and unknown risks and uncertainties that we face.   Please refer to Navigators' most recent reports on Forms 10-K and 10-Q and its other filings with the Securities and Exchange Commission for a description of Navigators' business and the important factors that may affect that business.  Navigators undertakes no obligation to publicly update or revise any forward-looking statement.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Oboya receives an important order in USA20.8.2019 09:31:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary Oboya Metal Qingdao Co. Ltd. in Qingdao, China received an order from an existing customer in the United States. The order value amounted to approximately USD 0.37 million, corresponding to approximately SEK 3.59 million. The order concerns delivery of flower trolleys and will be delivered from September until October 2019. The order value amounts to USD 0.37 million, corresponding to approximately SEK 3.59 million. The existing customer is one of the leading logistics, transport and service companies in the cultivation industry in North America. The flower trolleys will be used for efficient transport as well as for the exposure of plants or flowers in stores. "It is gratifying that there is continued demand for Oboya's products in the US, despite the current trade conflict between China and the US. We will continue to establish ourselves in the market and thereby gradually increase our market sh

Conditions for sale of Riksbank certificates20.8.2019 09:30:00 CESTPress release

AUCTION DATE: AUG 20, 2019 START DATE: AUG 21, 2019 MATURITY DATE: AUG 28, 2019 NOMINAL AMOUNT: 414.0 BLN FIXED RATE: -0.25 % ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON AUG 20, 2019, AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 414.0 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CET/CEST) ON AUG 20, 2019. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat